Updates from Readily Diagnostics — research milestones, partnerships, awards and company news.
We're proud to announce that Readily has received a grant from the Gates Foundation to develop a point-of-care molecular test for the most common sexually transmitted infections, chlamydia, gonorrhea and trichomoniasis, designed for use in low- and middle-income countries.
Readily Diagnostics has recruited Pernilla Roxin as Chief Operating Officer, strengthening the management team as the company moves toward commercialization.
Readily is one of 46 companies selected to pitch live at Techarena 2025, Scandinavia's largest startup and scaleup event.
Readily Diagnostics welcomes Jon Wallgren as Senior Production Engineer, reinforcing the team's capability to bring high-quality diagnostic products to market.
Readily's CEO and co-founder Liza Löf has been awarded the 2024 SKAPA Prize for Uppsala County, Sweden's largest and longest-running innovation award.
Readily Diagnostics has successfully closed a €1.6M capital round, led by founders and existing shareholders and joined by new investors including the Beijer Foundation and LF Uppsala.
Readily Diagnostics has been awarded a grant from the Bio-X Accelerate Program to advance the development of its next-generation rapid diagnostic tests for respiratory diseases.
